Neurobiology of Treatment Responses in MDD

University of Utah

Overview

The primary study intent is to examine biological mechanisms associated with acute and chronic treatment responses in major depressive disorder (MDD). It is hypothesized that treatment responsiveness, representing endogenous opioid system function, will be associated with acute improvements in mood state over a 10-week treatment trial in MDD. Potential (bio) markers of treatment effects will be tested against psychophysical responses to placebo and active treatments.

Volunteers will be randomized to receive placebo pills or a commercially available SNRI for 10 weeks. Volunteers will undergo imaging with structural and functional MRI and PET with \[11C\]carfentanil to determine baseline μOR BPND and changes in BPND measures during acute i.v. medication administration at the time of scanning before and after the 10-week treatment period. To elicit the activation of µ-opioid-mediated neurotransmission in the scanner, we utilize the introduction of medication (active or inactive) 1mL into an intravenous port every 4 minutes, 15 sec per infusion, starting 45 minutes after radiotracer administration, until scan completion. Participants are made aware that the study drug will be administered at the time a computer-generated human voice recording reads a second-by-second count of the infusion timing (15 sec).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Conditions

Major Depressive Disorder

Interventions

DuloxetineDRUG

10 week treatment

PlaceboDRUG

10 week treatment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meet DSM V criteria for Major Depressive Episode, single episode or recurrent, for at least a month; * Unmedicated for at least 10 half-lives of the previous AD used; * Willing to limit the introduction of any new treatments during the study; * 18 - 55 years of age; * Right handed; * Capable of giving written informed consent; * Hamilton Depression Rating Scale (17-item HDRS, not including atypical features) \>15 at screening and randomization; Exclusion Criteria: * Major medical illness (e.g., cancer, HIV, Hepatitis C, etc.) or concurrent, untreated, or symptomatic medical illnesses, including acute or ongoing pain, autoimmune or inflammatory disease; * Use of narcotic analgesics within the last 6 months or regular use of sleeping aids (including benzodiazepines and related compounds), more than twice a week; * Recent history of substance abuse (within the last 6 months) or history of substance dependence (lifetime); * Other comorbid psychiatric illnesses, such as Bipolar Disorder, Obsessive Compulsive Disorder, Panic Disorder, any psychosis, or Axis II diagnoses. Generalized Anxiety and Social Anxiety Disorders will NOT be considered exclusionary given their common association with MDD * Concurrent participation in other therapeutic trials; * Pregnancy/nursing; * Ongoing treatment with medications with psychotropic properties; * Contraindications to PET or MRI methods; * Impairments, activities or situations that would prevent completion of the study protocol; * Prior non-response to duloxetine; * Active suicidal ideation. * Urine screens positive for opioids or any substances of abuse. * Allergy to fentanyl (because of structural similarity to the radiotracer \[11C\]carfentanil to be employed in the study).

Locations (1)

University of Utah

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

mu-opioid receptor binding capacity

derived from PET scans

Time frame: 10 weeks

depression score

HRSD-17 score

Time frame: 10 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.